Concomitant administration should be used with caution in patients with mild and moderate hepatic impairment and is contraindicated in patients with severe hepatic impairment (see section 4.3).
Samanaikainen käyttö potilaille, joilla on vakava maksan toimintahäiriö, on kontraindisoitua (ks. kohta 4. 3).